$COV.ax CLEO Establishes U.S. Lab Infrastructure Ahead of Clinical Validation.
️ ▪️ CLEO has commenced preparations for #clinicalvalidation (CV), the final major clinical testing program supporting its #FDA 510(k) submission
▪️ Clinical testing infrastructure established at #CLIA-certified laboratory, Asuragen, with inter-laboratory reproducibility studies underway
▪️ CV program will involve testing ~1,470 #samples across three study populations to evaluate clinical #performance of CLEO's Pre-Surgical #OvarianCancer Test
▪️Testing anticipated to commence within the next month, supporting CLEO's planned FDA 510(k) submission in H1 CY2027.
Link to release: bit.ly/4kL8JGe
$COV #CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
4
157
$COV.ax CLEO Screening Test Meets Rigorous Performance Targets in First Proof-of-Concept Study.
▪️ Prototype #ScreeningTest has met and exceeded its pre-defined performance thresholds in its first proof-of-concept study of 247 individuals
▪️ In a cohort enriched with 62 Stage I cancers, being the most challenging target with the greatest survival benefit, CLEO’s prototype achieved (#sensitivity / #specificity):
− High-risk screening: 92.2% / 98.7% (against minimum 90.0% / 90.0%)
− General population screening: 75.0% / 100.0% (against minimum 75.0% / 99.6%)
▪️ Outperformed gold-standard #CA125 with Area Under the Curve (AUC) of 0.99 for Stage I and 0.98 for all-stage cancers
▪️ Development now progressing to bridging and expanded cohort studies, ahead of evaluation in prospectively collected intended-use populations.
Link to release: bit.ly/4i6IZ4b
$COV #CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
$COV.ax CLEO Commences Analytical Validation Ahead of FDA Submission.
▪️ #AnalyticalValidation (#AV) has commenced following receipt of the first batch of test kits from @biotechne and completion of the required pre-validation activities
▪️ Marks the start of formal regulatory testing of CLEO's #assay, generating critical analytical #performance data to support the Company’s #FDA 510(k) submission
▪️ AV will evaluate three independently manufactured batches to demonstrate assay precision, reproducibility, manufacturing consistency and analytical robustness
▪️ In parallel to AV, CLEO will progress to #ClinicalValidation to test its pivotal U.S. clinical trial and control samples.
Link to release: bit.ly/4hU4ZiS
$COV #CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
4
317
REMINDER: CLEO to Present at MST Biotech & Healthcare Webinar Series Today.
Register to attend the webinar: bit.ly/MSTbiohealthwebinar
Replying to @Cleodiagnostics
@Cleodiagnostics Dayna Louca will present Cleo's #ovariancancer blood test opportunity at the MST Access Biotech & Healthcare Webinar Series on 6th October. The event will feature three innovative ASX-listed #biotech and #healthcare companies at the forefront of disease #diagnostics innovation.
𝗠𝗦𝗧 𝗔𝗰𝗰𝗲𝘀𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 & 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗦𝗲𝗿𝗶𝗲𝘀: 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀
Hosted by Professor Bruce Robinson
📅 Tuesday 6th October 2026
🕰️ 4-5pm
🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: lnkd.in/g8TX8a-D
#CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
1
4
105
$COV CLEO Files Patents for its #OvarianCancer Screening Test.
▪️ CLEO has filed two new provisional #patent applications to protect #intellectualproperty arising from the development of its screening test
▪️ Both filings relate to candidate #biomarker combinations and their application to the early detection of #ovariancancer
▪️ Intellectual property protection to be established ahead of initial proof-of-concept screening data, expected in early Q4 CY2026.
Link to release: bit.ly/47oR13t
$COV.ax #CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
3
249
$COV Commences Ovarian Cancer Screening Test Development.
▪️ Prototype development of CLEO’s multi-marker screening #bloodtest is underway
▪️ Screening represents a $150B global addressable market for population screening, to identify early-stage ovarian cancers in #asymptomatic women
▪️ #screeningtest development will run in parallel with CLEO’s initial pre-surgical test that is on track for #FDA submission in H1 CY2027
▪️ Initial proof-of-concept screening test data expected early next Quarter, with the Company targeting finalisation of test panel architecture by end of CY2026.
Link to release: bit.ly/4rqHLoC
#CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
5
144
@Cleodiagnostics Dayna Louca will present Cleo's #ovariancancer blood test opportunity at the MST Access Biotech & Healthcare Webinar Series on 6th October. The event will feature three innovative ASX-listed #biotech and #healthcare companies at the forefront of disease #diagnostics innovation.
𝗠𝗦𝗧 𝗔𝗰𝗰𝗲𝘀𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 & 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗦𝗲𝗿𝗶𝗲𝘀: 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀
Hosted by Professor Bruce Robinson
📅 Tuesday 6th October 2026
🕰️ 4-5pm
🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: lnkd.in/g8TX8a-D
#CleoDX $COV.ax #ovarian #cancer #medtech #womenshealth ASX.COV #invest
$COV Selects CLIA-Certified Laboratory for Pivotal U.S. Clinical Validation
▪️ CLEO has engaged #CLIA-certified U.S. laboratory, @Asuragen, to assist in executing its pivotal #clinicalvalidation program for its Pre-Surgical #ovariancancer Test
▪️ The program will generate clinical performance data from over 1,300 #samples to establish the #sensitivity, #specificity, #PPV and #NPV of CLEO’s test
▪️ Extends CLEO’s strategic relationship with @biotechne across commercial test kit manufacture, the Ella™ diagnostic platform and pivotal U.S. clinical testing.
Link to release: bit.ly/3T1s1fd
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
3
164
$COV Receives First Batch of Commercially Manufactured Test Kits
▪️ #AnalyticalValidation set to commence following receipt of first production batch of #testkits manufactured by @biotechne (NASDAQ:TECH)
▪️ Three independently manufactured batches will be evaluated to demonstrate #assay precision, reproducibility, manufacturing consistency and analytical robustness
▪️ First batch to establish core #performance characteristics of CLEO’s eight-#biomarker assay, providing reference for subsequent production batches to be evaluated
▪️ AV will generate critical analytical performance data required to progress CLEO’s commercial assay into next #clinicalvalidation phase
▪️ CLEO continues to target planned #FDA 510(k) submission in H1 CY2027.
Link to release: bit.ly/46ECKPM
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
Appreciate @JMM_Australia (JMM) team for hosting Cleo Diagnostics at its East Coast #Investor event.
Our message here was simple, #ovariancancer is often diagnosed late, resulting in a largely unchanged 5-year survival rate of just 49% (compared to #breastcancer with a 92% 5-year survival rate).
It was pleasing to talk to many investors in the room about their own personal experiences and their shared support for a solution.
The urgent need for early and accurate detection could not be stronger.
CLEO's simple and accurate #bloodtest is built to close the gap. Our initial commercially available test is in the final stages ahead of FDA 510(k) submission in H1 CY2027.
CLEO is pioneering the transformation of ovarian cancer detection with the ultimate goal of delivering positive outcomes for #womenshealth globally.
Watch the presentation here: bit.ly/4xSCgBe
ASX.COV #invest #ovariancancer #womenshealth #diagnostics #medtech #ASX
What an afternoon at the 2026 JMM East Coast Investor Lunch. We’re pleased to share some of the highlights, coverage and content from this year’s event.
📺Watch YouTube playlist - youtube.com/playlist?list=PL…
1
226
$COV.ax Enters Analytical Validation Phase
▪️ Following completion of commercial assay development and key preparation activities, CLEO now enters the formal pre-#FDA submission validation phase
▪ #analyticalvalidation expected to commence next month upon receipt of first manufactured batch of CLEO’s test kits from Bio-Techne
▪ Three-batch validation design adopted to demonstrate assay reproducibility and manufacturing consistency in accordance with FDA requirements
▪ #clinicalvalidation preparations advanced, supporting efficient progression towards FDA 510(k) submission in CY2027.
Link to release: bit.ly/4wDlOUK
#CleoDX #ovariancancer #cancer #medtech #womenshealth ASX.COV #invest
$COV to present this week at @VEvents_RIU Gold Coast Investment Showcase Event.
Event details:
When: Thursday, 11 June 2026
Time: 11.15am AEST
Where: In-person - JW Marriott Gold Coast Resort & Spa, QLD.
Register to attend: bit.ly/COVGCinvest
#CleoDX #ovariancancer #ovarian #cancer #medtech #womenshealth @jaxoncrabb ASX.COV #invest
3
243
CLEO Establishes U.S. Reimbursement Pathway Ahead of FDA Submission
▪️ CLEO to enter U.S. market under miscellaneous CPT code 81599 immediately post-FDA clearance, enabling early billing and real-world utilisation data capture
▪ Reimbursement determined via cross-walking to comparable multi-biomarker tests, which have reported reimbursement levels of ~US$500-US$900 per test, supporting CLEO’s initial pricing discussions
▪ Represents the first step toward securing a dedicated CPT code, supporting long-term reimbursement and commercial scale.
Link to release: cdn-api.markitdigital.com/ap…
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
Cleo Diagnostics Quarterly Activities Report March 2026.
Link to release: bit.ly/MarchQuarter
#CleoDX #ovariancancer #ovarian #cancer #medtech #womenshealth #invest ASX.COV
67
$COV.ax Commences Kit #Manufacturing Program
ahead of #FDA Submission.
▪️Initial phase of staged manufacturing program now underway with @biotechne to support production of CLEO’s test kits
▪ Follows completion of sample collection for CLEO’s pivotal #U.S. #clinicaltrial, marking transition to analytical validation and clinical sample testing
▪ Staged approach designed to reduce technical and manufacturing risk ahead of full-scale test kit production and FDA 510(k) submission.
Link to release: bit.ly/4sZ45Vy
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
4
439
$COV.ax reaches Key Milestone with Completion of
Sample Collection for Pivotal U.S. Clinical Trial.
▪️514 blood #samples collected for CLEO’s #clinicaltrial, representing a key step toward the Company’s #FDA submission for its Pre-Surgical #OvarianCancer Test
▪ 624 women enrolled across 19 U.S. sites, demonstrating strong trial execution supporting a robust final study dataset
▪ Binding manufacturing agreement for test kit production remains in the final stages following recent #biomarker panel optimisation
▪ Achieving sample target moves CLEO into final execution phase comprising pre-verification, analytical validation, sample testing, clinical data analysis & validation.
Link to release: bit.ly/3Obrnt5
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
3
857
$COV.ax Completes #Biomarker Panel #Optimisation Ahead of FDA 510(k) Submission.
▪️Biomarker panel expanded from five to eight biomarkers, improving analytical robustness, reproducibility and commercial manufacturability.
▪ Optimised panel has been designed for high #throughput Ella™ platform, supporting scalable global deployment without compromising #performance.
▪ Binding #manufacturing agreement imminent, with partner aligned and experienced in development and production of the selected biomarkers.
▪ Test kit production to support #FDA analytical validation activities to commence immediately following execution.
Link to release: bit.ly/4lSUM7W
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
$COV.ax Confirms Next Generation Platform to Deliver its Ovarian Cancer Test.
▪️Bio-Techne’s Ella™ selected, a next-generation automated #ELISA platform, as the #immunoassay instrument for CLEO's #ovariancancer blood test.
▪️@biotechne (NASDAQ: TECH) is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments and immunoassay technologies.
▪️The Ella™ platform can deliver materially improved assay sensitivity, precision and automation compared with conventional ELISA platforms.
▪️Binding agreement discussions well progressed with Bio-Techne for analytical validation to enable sample testing and clinical trial completion.
▪️Both parties aligned to enter long-term manufacturing supply agreement following completion of these activities.
Link to release: bit.ly/4tCUXI1
#CleoDX #ovarian #cancer #medtech #womenshealth ASX.COV #invest
February is Ovarian Cancer Awareness Month.
Ovarian cancer is often called the “silent cancer” — not because it has no symptoms, but because the symptoms are vague, common, and frequently overlooked.
At Cleo Diagnostics, we’re working to change that with our simple blood test for earlier, more accurate detection.
Awareness matters. Earlier answers matter.
#OCAM #CleoDX $COV.ax #ovariancancer #ovarian #cancer #medtech #womenshealth ASX.COV #invest
2
79






